However, LCNEC is characterized by a high expression level of programmed death-ligand 1 (PD-L1) and a median tumor mutational burden (TMB) of 5.42 mutations per megabase (Mut/Mb), suggesting a biological rationale for the efficacy of immunotherapy in LCNEC (22–24). The gene discussed is CD274; the disease is neoplasm.